Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?: Can we avoid a catastrophic second valley of death?

Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?: Can we avoid a catastrophic second valley of death?
复制标题

DOI:
10.15252/embr.202256661
复制
发表时间:
2023-02-06
期刊:
影响因子:
7.7
通讯作者:
--
中科院分区:
生物学2区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

先进的基因和细胞疗法由于其高成本和低患者群体而面临第二个“死亡谷”的风险。由于这些是挽救生命的疗法,因此迫切需要采取措施防止其退出市场。
Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.
呼吁采取综合方法来提高美国罕见病研究的效率、公平性和可持续性。
DOI: 10.1038/s41588-022-01027-w
发表时间: 2022-03
期刊: NATURE GENETICS
影响因子: 30.8
作者:
Halley, Meghan C.;Smith, Hadley Stevens;Ashley, Euan A.;Goldenberg, Aaron J.;Tabor, Holly K.
通讯作者: Tabor, Holly K.
DOI: 10.1056/nejmoa0905955
发表时间: 2010-07-08
影响因子: 158.5
作者:
Rama, Paolo;Matuska, Stanislav;Pellegrini, Graziella
通讯作者: Pellegrini, Graziella
DOI: 10.1038/nature24487
发表时间: 2017-11-16
期刊: Nature
影响因子: 64.8
作者:
Hirsch T;Rothoeft T;Teig N;Bauer JW;Pellegrini G;De Rosa L;Scaglione D;Reichelt J;Klausegger A;Kneisz D;Romano O;Secone Seconetti A;Contin R;Enzo E;Jurman I;Carulli S;Jacobsen F;Luecke T;Lehnhardt M;Fischer M;Kueckelhaus M;Quaglino D;Morgante M;Bicciato S;Bondanza S;De Luca M
通讯作者: De Luca M
DOI: 10.1056/nejmoa2108544
发表时间: 2021-12-09
影响因子: 158.5
作者:
Kueckelhaus, Maximilian;Rothoeft, Tobias;Hirsch, Tobias
通讯作者: Hirsch, Tobias
DOI: 10.1016/s0140-6736(17)31611-2
发表时间: 2017-09-23
期刊: LANCET
影响因子: 168.9
作者:
McDonald, Craig M.;Campbell, Craig;Mercuri, Eugenio
通讯作者: Mercuri, Eugenio